Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Jade Biosciences, Inc. (JBIO)

Jade Biosciences Licenses JADE301 Antibodies From Paragon in Deal Up to $22.0 Million

Neutral Impact 3 of 5 product/contract Written later

Jade Biosciences entered into a license agreement with Paragon Therapeutics on June 29, 2026, granting it exclusive worldwide rights to certain monospecific antibodies and products targeting an undisclosed target. The company must pay Paragon milestone payments of up to $22.0 million, sublicensing fees of up to approximately $20.1 million, and royalties on net sales, which shows the financial commitments tied to the program.

Key points

  • Agreement dated June 29, 2026; Jade already paid a $1.5 million candidate nomination fee in January 2026.
  • Milestones total up to $22.0 million, including a $2.5 million payment upon first human dosing in a Phase 1 trial.
  • Royalties of low to mid-single-digit percentage on monospecific product sales and mid-single-digit on multispecific product sales.
  • Paragon will not run new campaigns generating monospecific antibodies against the Target for at least five years; full text to be filed with the 10-Q for the quarter ending June 30, 2026.

The filing

CompanyJade Biosciences, Inc. (JBIO)
Form8-K, current report
Filed with the SECJul 1, 2026, 4:41 PM ET
Accession number0001193125-26-292704

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.